Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Video gone

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von May 15, 2021 6:38am

324 Views

Post# 33209425

RE:RE:Video gone

I emailed Sarah at RVX, IR re video takedown yesterday:

"Hello Sarah, Is there a particular reason why yesterday's presentation is no longer available for viewing?"

Her response:

"Thank you for the email - unfortunately a you tube algorithm took down the video due to the mention of “vaccine” so we have appealed and hope it’s resolved soon.

Regards,
RVX"

glta
G1945V

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec